NO20070950L - Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein. - Google Patents

Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.

Info

Publication number
NO20070950L
NO20070950L NO20070950A NO20070950A NO20070950L NO 20070950 L NO20070950 L NO 20070950L NO 20070950 A NO20070950 A NO 20070950A NO 20070950 A NO20070950 A NO 20070950A NO 20070950 L NO20070950 L NO 20070950L
Authority
NO
Norway
Prior art keywords
preparations
methods
angiopoietin
protein
cell
Prior art date
Application number
NO20070950A
Other languages
English (en)
Other versions
NO342525B1 (no
Inventor
Hans-Peter Gerber
Stuart Bunting
Xiao Huan Liang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20070950L publication Critical patent/NO20070950L/no
Publication of NO342525B1 publication Critical patent/NO342525B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

ANGPTL4-preparater og fremgangsmåter for å anvende slike preparater, og agonister eller antagonister derav, til diagnostisering og behandlingen av sykdommer eller forstyrrelser er inkludert, inkludert fremgangsmåter for å modulere celleproliferasjon, celleadhesjon og cellemigrasjon.
NO20070950A 2004-07-20 2007-02-19 Et angiopoietinlignende 4-protein (ANGPTL4) eller en nukleinsyre som koder for ANGPTL4 eller en ANGPTL4-agonist, deres anvendelse og deres anvendelse for fremstilling av et medikament. NO342525B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58987504P 2004-07-20 2004-07-20
PCT/US2005/025650 WO2006014678A2 (en) 2004-07-20 2005-07-19 Compositions and methods of using angiopoietin-like 4 protein

Publications (2)

Publication Number Publication Date
NO20070950L true NO20070950L (no) 2007-04-12
NO342525B1 NO342525B1 (no) 2018-06-04

Family

ID=35787695

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070950A NO342525B1 (no) 2004-07-20 2007-02-19 Et angiopoietinlignende 4-protein (ANGPTL4) eller en nukleinsyre som koder for ANGPTL4 eller en ANGPTL4-agonist, deres anvendelse og deres anvendelse for fremstilling av et medikament.

Country Status (19)

Country Link
US (3) US7371384B2 (no)
EP (1) EP1781698B1 (no)
JP (2) JP5318412B2 (no)
KR (1) KR20070061524A (no)
CN (1) CN101080419B (no)
AU (1) AU2005269758B2 (no)
BR (1) BRPI0513477A (no)
CA (1) CA2574791A1 (no)
DK (1) DK1781698T3 (no)
HK (1) HK1110602A1 (no)
HU (1) HUE029170T2 (no)
IL (4) IL180752A0 (no)
LT (1) LT1781698T (no)
MX (1) MX2007000783A (no)
NO (1) NO342525B1 (no)
NZ (2) NZ552957A (no)
RU (2) RU2380411C2 (no)
WO (1) WO2006014678A2 (no)
ZA (1) ZA200701184B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
HUE029170T2 (en) 2004-07-20 2017-03-28 Genentech Inc Preparations and methods for the use of angiopoietin-like protein 4
ZA200705980B (en) * 2005-01-07 2009-01-28 Lexicon Pharmaceuticals Inc Monoclonal antibodies against angiopoietin-like protein 4 (ANGPTL4)
WO2007024723A2 (en) * 2005-08-19 2007-03-01 Washington University In St. Louis Methods and compositions for treating gastrointestinal radiosensitivity in a subject
ZA200807714B (en) * 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
US8003621B2 (en) 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
AU2009308124B2 (en) * 2008-10-20 2014-12-11 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
EP2488640B1 (en) 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferative agent
AU2011203986C1 (en) * 2010-01-08 2015-03-05 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
JP5828152B6 (ja) * 2010-01-20 2018-09-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血管内皮細胞バリアの完全性の保存ための方法及び医薬的組成物
US9139629B2 (en) 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) * 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
KR20130132375A (ko) * 2010-06-05 2013-12-04 더 유에이비 리서치 파운데이션 신장 증후군 및 관련 질환을 치료하는 방법
WO2012094658A2 (en) * 2011-01-08 2012-07-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102692496B (zh) * 2011-03-21 2015-10-28 上海市肿瘤研究所 Angptl4作为缺氧检测的标志物及其应用
CN102692500B (zh) * 2011-03-21 2015-06-10 上海市肿瘤研究所 Angptl4作为血清学检测肝癌转移的标志物及其应用
CN102242198A (zh) * 2011-05-25 2011-11-16 信阳师范学院 通过angptl4基因多态性进行牛育种方法
SG10201913683WA (en) * 2011-06-21 2020-03-30 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
PE20141518A1 (es) * 2011-07-01 2014-11-17 Monsanto Technology Llc Metodos y composiciones para la regulacion selectiva de la expresion de proteinas
SG10201607346XA (en) * 2011-08-08 2016-10-28 Univ Nanyang Tech Angiopoietin-like 4 and its use in modulating cell leakiness
KR20140101397A (ko) 2011-12-09 2014-08-19 메타볼릭 파마슈티칼즈 피티와이 엘티디 성장 호르몬 단편들의 사용
TWI641687B (zh) * 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2874708B1 (en) 2012-07-19 2020-04-08 Nanyang Technological University A fragment of angiopoietin-like 4 for use in wound healing
CN105229024A (zh) * 2013-03-15 2016-01-06 Uab研究基金会 肾病综合征及相关病状的治疗方法
CN111593051A (zh) 2013-05-01 2020-08-28 Ionis制药公司 组合物和方法
WO2015009948A1 (en) * 2013-07-19 2015-01-22 Regents Of The University Of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
CA2931510A1 (en) 2013-12-24 2015-07-02 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2015123576A2 (en) * 2014-02-17 2015-08-20 The Brigham And Women's Hospital, Inc. Targeted nanoparticle compositions and methods of their use to treat obesity
EP3137605B1 (en) 2014-05-01 2020-10-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
PT3177642T (pt) * 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
CN105021827B (zh) * 2015-07-17 2016-09-28 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
PT3324732T (pt) 2015-07-22 2023-02-14 Monsanto Technology Llc Métodos e composições para a regulação seletiva da expressão de proteínas
BR112018003291A2 (pt) 2015-11-06 2018-09-25 Ionis Pharmaceuticals, Inc. modulando a expressão da apolipoproteina (a)
CA3029121A1 (en) * 2016-06-29 2018-01-04 Crispr Therapeutics Ag Compositions and methods for gene editing
CN113015803A (zh) * 2018-11-13 2021-06-22 利皮药业有限公司 影响脂肪酸代谢调控的angptl4寡核苷酸
JP2023511245A (ja) * 2019-11-06 2023-03-17 ノースウェスタン ユニバーシティ Ｖｅ－ｐｔｐホスファターゼの阻害は腎臓を虚血再灌流障害から保護する
CA3164050A1 (en) 2019-12-09 2021-06-17 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
WO2001053486A1 (en) 1999-03-08 2001-07-26 Genentech, Inc. Compositions and methods for the treatment of tumor
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US20030207375A1 (en) 1997-10-24 2003-11-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1931599A (en) 1997-12-19 1999-07-12 Zymogenetics Inc. Angiopoietin homolog, dna encoding it, and method of making it
JP2002516067A (ja) 1998-03-02 2002-06-04 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド 新規ｆｄｒｇタンパク質および核酸分子、ならびにそのための用途
US20030099994A1 (en) 1998-03-02 2003-05-29 Millennium Pharamceuticals, Inc. Novel FDRG protein and nucleic acid molecules and uses therefor
JP2000026767A (ja) 1998-05-01 2000-01-25 Daikin Ind Ltd 熱硬化性粉体塗料組成物
JP2002518010A (ja) 1998-06-16 2002-06-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９４個のヒト分泌タンパク質
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001053455A2 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2000308488A (ja) 1999-02-23 2000-11-07 Herikkusu Kenkyusho:Kk 血管新生に関連するタンパク質および該タンパク質をコードする遺伝子
AU3391200A (en) 1999-03-04 2000-09-21 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
JP2003501011A (ja) 1999-04-09 2003-01-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
KR100634926B1 (ko) 1999-04-16 2006-10-17 제넨테크, 인크. 혈관 내피 세포 성장 인자 변이체 및 그의 용도
AU5979300A (en) 1999-07-02 2001-01-22 Bayer Aktiengesellschaft Angiopoietin-6 and uses thereof
WO2001005825A2 (en) 1999-07-16 2001-01-25 Hyseq, Inc. Nucleic acid sequences encoding putative angiopoietin proteins
CA2379925A1 (en) 1999-07-20 2001-01-25 Curagen Corporation Polypeptides and polynucleotides encoding same
US20030207348A1 (en) 1999-07-20 2003-11-06 Shimkets Richard A. Polypeptides and polynucleotides encoding same
AU2001233041A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Novel nucleic acids and polypeptides
CN1315451A (zh) 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人血管形成素类似因子45和编码这种多肽的多核苷酸
WO2001077151A2 (en) 2000-04-07 2001-10-18 Millennium Pharmaceuticals, Inc. Fdrg proteins and nucleic acid molecules and uses therefor
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
CN1170850C (zh) 2000-09-19 2004-10-13 上海市肿瘤研究所 人血管生成素样蛋白和编码序列及其用途
US20030120056A1 (en) 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
WO2003000865A2 (en) 2001-03-27 2003-01-03 Human Genome Sciences, Inc. Human secreted proteins
WO2002101039A1 (en) 2001-06-08 2002-12-19 Sankyo Company, Limited Method of testing drug for treating or preventing diseases such as hyperlipemia
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040038230A1 (en) 2001-11-05 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2460653A1 (en) 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002348286B2 (en) 2001-11-16 2008-04-03 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 Angptl3
AU2002359464A1 (en) 2001-11-30 2003-06-17 Genvec, Inc. Angiopioetin related factors
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2003251397B2 (en) 2002-06-05 2009-10-01 Genentech, Inc. Compositions and methods for liver growth and liver protection
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
CA2499791A1 (en) 2004-03-30 2005-09-30 F. Hoffmann-La Roche Ag Angptl4/fiaf as marker for ppardelta modulation
HUE029170T2 (en) * 2004-07-20 2017-03-28 Genentech Inc Preparations and methods for the use of angiopoietin-like protein 4
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
ZA200705980B (en) * 2005-01-07 2009-01-28 Lexicon Pharmaceuticals Inc Monoclonal antibodies against angiopoietin-like protein 4 (ANGPTL4)

Also Published As

Publication number Publication date
AU2005269758B2 (en) 2011-11-03
LT1781698T (lt) 2016-09-26
ZA200701184B (en) 2008-07-30
US7371384B2 (en) 2008-05-13
AU2005269758A1 (en) 2006-02-09
RU2007106075A (ru) 2008-08-27
IL206483A0 (en) 2010-12-30
US8633155B2 (en) 2014-01-21
IL206483A (en) 2011-11-30
IL218357A0 (en) 2012-04-30
US20100172915A1 (en) 2010-07-08
DK1781698T3 (en) 2016-10-03
MX2007000783A (es) 2007-04-09
BRPI0513477A (pt) 2008-05-06
JP2008507531A (ja) 2008-03-13
IL209823A0 (en) 2011-02-28
NZ592973A (en) 2013-01-25
IL218357A (en) 2015-01-29
CN101080419B (zh) 2014-07-02
EP1781698A2 (en) 2007-05-09
EP1781698B1 (en) 2016-07-06
JP5318412B2 (ja) 2013-10-16
HUE029170T2 (en) 2017-03-28
JP2011235179A (ja) 2011-11-24
HK1110602A1 (en) 2008-07-18
CA2574791A1 (en) 2006-02-09
US20060093606A1 (en) 2006-05-04
CN101080419A (zh) 2007-11-28
WO2006014678A2 (en) 2006-02-09
IL180752A0 (en) 2007-06-03
US20070054856A1 (en) 2007-03-08
KR20070061524A (ko) 2007-06-13
RU2380411C2 (ru) 2010-01-27
NZ552957A (en) 2011-06-30
NO342525B1 (no) 2018-06-04
RU2009137017A (ru) 2011-04-20
WO2006014678A3 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
NO20064192L (no) Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser
ATE496636T1 (de) Verwendung von agonisten und antagonisten von interleukin-33 (il-33)
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
NO20056236L (no) Behandling med anti-VEGF-antistoffer
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
EA200971077A1 (ru) Гетероциклические модуляторы киназы
NO20091989L (no) Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
BR112022008821A2 (pt) Ligantes de pseudoquinase tyk2
BR112023002455A2 (pt) Anticorpos fgfr3 e métodos de uso
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
DE60230194D1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7-dimethylbicycloä2.2.1ühept-1-ylmethanesulphonamide-familie
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE536549T1 (de) Galnts als modifikatoren des igfr-weges und verwendungsverfahren
DK1572931T3 (da) Fremgangsmåder og sammensætninger til modulering og påvisning af WISP-aktivitet
DK1196188T3 (da) VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser
UA93679C2 (en) Compounds modulating c-kit and c-fms activity and uses therefor

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees